AuthorisedTherapeutic confirmatory (Phase III)Interventional

CANDISHORT : A randomized study of a short duration therapy for candidemia

This research study, called CANDISHORT, is investigating how effective shorter treatment courses are for a fungal blood infection known as candidemia. Candidemia happens when yeast spreads into your bloodstream. The study aims to compare several existing antifungal medications, including voriconazole, anidulafungin, caspofungin, amphotericin B liposome, fluconazole, and micafungin, to see if a shorter treatment duration can effectively clear the infection. Researchers will be looking at how well patients recover at 28 days after the infection is first cleared from their blood. The main goal is to find out if reducing the length of antifungal treatment is safe and effective, potentially meaning fewer side effects and a quicker return to health for patients with uncomplicated candidemia.

At a glance

Status

Authorised

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Assistance Publique Hopitaux De Paris

Enrolment target

399

Start

06 Mar 2026

Uncomplicated candidemia

What is this study about?

This study, called CANDISHORT, is all about finding the best way to treat a type of blood infection caused by a fungus, often referred to as 'candidemia'. Think of it like a yeast infection, but in your bloodstream. When this happens, doctors usually give medicine to kill the fungus. This study wants to find out if giving these medicines for a shorter amount of time is just as good, or even better, than the usual longer treatments.

We already have several good medications for candidemia, like voriconazole, anidulafungin, and fluconazole (to name a few that are being tested). This study isn't trying out a brand new, never-before-seen medicine. Instead, it's comparing existing treatments in a new way – by looking at how well they work over a shorter period. The hope is that a shorter treatment might mean fewer side effects for patients, less time spent in hospital, and a quicker return to normal life.

The main thing the doctors will be checking is how well people recover about a month after the fungus is no longer found in their blood. They will also look at whether the infection comes back, if any other parts of the body get infected, and how the treatments affect things like liver function. Ultimately, the study aims to improve how we care for people with this type of infection, making treatment as effective and gentle as possible.

Key takeaways

This study aims to find shorter, effective treatments for a fungal blood infection.
It uses existing, approved antifungal medications.
Participation involves regular check-ups and blood tests.
Both men and women aged 18 and over with uncomplicated candidemia can participate.
You can leave the study at any time without affecting your medical care.

Who may be eligible?

To join this study, you would need to be at least 18 years old. Both men and women are welcome to take part. The most important medical requirement is that you have been diagnosed with a specific type of fungal blood infection called 'uncomplicated candidemia'.

'Uncomplicated candidemia' means that the fungal infection is mainly in your bloodstream and hasn't spread widely or caused serious damage to other organs, and you don't have certain other health conditions that would make your case more complex.

Your doctor will carefully check your medical history and current health to make sure you fit all the study's requirements. This is to ensure the study is safe for you and that the results are clear and reliable for the researchers.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of candidemia (a fungal blood infection)?
Has your doctor told you that your candidemia is 'uncomplicated'?
Are you generally able to attend regular appointments for check-ups?
Are you comfortable with the idea of being randomly assigned a treatment plan?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be randomly assigned to receive one of the study treatments for a shorter duration than usual. This means neither you nor your doctor would choose which specific treatment you receive – it's decided by chance, like flipping a coin. You would receive one of several established antifungal medications that are already approved and widely used.

Throughout the study, you would have regular blood tests to check on the infection, how you're responding to treatment, and to monitor your liver function. There would be several check-ups and visits, including at the very beginning when you join, then around 14 days later, and again at 28 days after the fungus is no longer detected in your blood. There might also be a check-up at 45 days. The total duration of your active participation in terms of assessments would likely be around 1.5 to 2 months from when your blood infection clears, though the actual treatment duration would be shorter.

Potential risks and benefits

Taking part in a study like this could offer potential benefits, such as contributing to new knowledge that might improve care for future patients with candidemia. You would also receive close medical attention and monitoring from the study team. However, there are potential risks, as with any medical treatment. The medications used are existing treatments, meaning their known side effects (which can vary depending on the drug) will be discussed with you by your doctor. There is also the possibility that a shorter treatment might not be as effective for you as a longer one, or that the infection could return. You have the right to withdraw from the study at any time, for any reason, without affecting your standard medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is candidemia?

Candidemia is a fungal infection where certain types of yeast enter your bloodstream. It can make you very unwell.

Are the study drugs new and experimental?

No, all the medicines being studied are existing, approved antifungal drugs. The study is looking at shorter treatment times, not new drugs.

Why is 'uncomplicated' candidemia important?

Uncomplicated candidemia means the infection mainly stays in your blood and hasn't caused other serious problems. This helps the study focus on simple cases.

What does 'randomized' mean?

It means you would be put into a treatment group by chance, like drawing numbers from a hat. This helps ensure fair comparison between treatments.

Will I know which treatment I'm getting?

Usually, in studies like this, you and your doctor would know which of the standard treatments you are receiving.